08-28-06

EXPRESS MAIL NO. EV 898719997 US

Date Mailed: August 24, 2006

cgc



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of Boyer, José L., et al.	Art Unit: 1623
Application No. 09/643,138 (Now U.S. Patent No. 7,018,985)	Examiner: Owens, Jr., Howard V.
Filed: August 21, 2000 (Issued March 28, 2006)	Attorney Docket: 03678.0064.00US00
For: COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION	

REQUEST FOR CERTIFICATE OF CORRECTION

Certificate
AUG 30 2006
of Correction

ATTN: Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant hereby requests the Commissioner to issue a Certificate of Correction for the above-identified U.S. Patent No. 7,018,985 under 37 C.F.R. §1.322, to correct mistakes incurred through the fault of the Office, which mistake is clearly disclosed in the records of the Office. Applicants believe that no fee is due, however, the U.S. Patent and Trademark Office is authorized to charge any fee deficiency to deposit account 08-3038 references attorney docket number 03678.0064.00US00.

Applicants hereby request the following corrections in the above-captioned patent.

AUG 30 2006

THE CORRECTIONS

In the Specification:

Column 8, at line 66, change "n and p=0.1, or 2" to --n and p=0, 1, or 2--.

Column 9, at line 28, change "Z'=OH" to --Z'=H, OH,--.

Column 18, line 14, change "121.47 NHz" to --121.47 MHz--.

Column 19, line 53, change "(b **24**mg" to --(24mg--.

Column 20, line 43, change "β -10.13" to --δ -10.13--.

Column 20, line 53, change "β 4.10" to --δ 4.10--.

In the Claims:

Column 25, line 13, Claim 1, after "thereof", insert -- and a pharmaceutically acceptable carrier --.

Column 26, line 27, Claim 1, insert --wherein:-- before "X_1, X_2, and X_3 =O".

Column 27, line 32, Claim 1, change "0 to 5" to --1 to 5--.

Column 27, line 58, Claim 1, change "0 to 5" to --1 to 5--.

Column 28, lines 36-37, Claim 1, change "OR1, OR2, OR3, or OR4" to -- OR_1, OR_2, OR_3, or OR_4--.

Column 29, lines 4-5, Claim 1, change "1 to 3" to --0 to 3--.

Column 29, lines 21-22, Claim 1, change "1 to 3" to --0 to 3--.

Column 30, line 51, Claim 1, before "alkyl", delete --an--.

Column 31, line 67 through Column 32, line 2, Claim 1, delete "provided that they incorporate an amino residue from the C-6 position of the purine or the C-4 position of the pyrimidine;".

Column 32, line 8, Claim 1, delete ", as described above"

Column 32, line 14, Claim 1, change "aralkyloxy" to --aralkoxy--.

Column 32, lines 24-25, Claim 1, delete ", such as acetyl, benzoyl, phenylacyl, with or without substituents".

Column 32, line 27, Claim 1, delete "methyl, alkyl,".

Column 32, line 52, Claim 2, change "claim 1" to --claim 36--.

Column 33, line 24, Claim 10, change "a group" to --the group--.

Column 34, lines 11-12, Claim 19, delete "including skin flaps".

Column 34, line 12, Claim 19, delete "such as breast reduction".

Column 35, lines 8-10, Claim 35, delete "35. The pharmaceutical formulation according to claim **1**, wherein said formulation further comprises a pharmaceutical carrier."

Column 35, line 11, renumber "36" to --35--.

Column 35, line 14, renumber "37" to --36--.

Column 37, line 43, change "0 to 5" to --1 to 5--.

Column 38, line 1, change "0 to 5" to --1 to 5--.

Column 39, lines 11-12, change "1 to 3" to --0 to 3--.

Column 39, lines 26-27, change "1 to 3" to --0 to 3--.

Column 40, line 58, change "aryl, substituted" to --and substituted--.

Column 40, line 59, delete "ad substituted aryl,--.

Column 42, line 4, delete "alkylthio, alkyloxy,".

Column 42, lines 5-6, delete "aralkylamino, arylamino, diaralkylamino, and diarylamino,".

Column 42, line 6, before "where", insert --and dialkylamino--.

Column 42, lines 8-11, delete ", provided that they incorporate an amino residue from the C-6 position of the purine or the C-4 position of the pyrimidine".

Column 42, line 25, change "aralkyloxy" to --aralkoxy--.

Column 42, lines 35-36, delete ", such as acetyl, benzoyl, phenylacyl, with or without substituents".

Column 42, line 39, delete "methyl, alkyl,".

Column 42, line 66, renumber "38" to --37--.

Column 44, line 32, insert the following claims:

--38. The pharmaceutical formulation according to Claim 1, wherein said compound is Formula Ia, wherein

X_1, X_2, and X_3=O;

T, V, and W= O;

M= H, NH_4^+, Na^+ or other pharmaceutically-acceptable inorganic or organic counterion;

Y'= H, OH, or OR_1, where OR_1 falls under the definition of general formula III;

Z'= OH or OR_2, where OR_2 falls under the definition of general formula III;

Z= OH or OR_3, where OR_3 falls under the definition of general formula III;

Y= H, OH, or OR_4, where OR_4 falls under the definition of general formula III;

provided that at least one of Y', Z', Z, and Y is OR_1, OR_2, OR_3, or OR_4, respectively;

D_1 =O;

D_2 =O;

B and B' are purine or pyrimidine residues according to general formulas IV and V;

m and p= 0, 1 or 2;

n= 0 or 1.

such that the sum of m+n+p is from 0 to 5.

39. The pharmaceutical formulation according to Claim 1, wherein said compound is Formula Ib, wherein

A is M or alkyl;

X_1 and X_2= O;

T, V, and W= O;

M is selected from the group consisting of H, NH_4^+, Na^+ and other pharmaceutically-acceptable inorganic or organic counterion;

Y'= OR_1, where OR_1 falls under the definition of general formula III;

Z'= OR_2, where OR_2 falls under the definition of general formula III;

D_1 =O or C;

B' is purine or pyrimidine residue according to general formulas IV and V;

n and p are 0, 1, or 2 such that the sum of n+p is from 0 to 3.

40. The pharmaceutical formulation according to Claim 1, wherein

R_{10} and R_{14} are selected from the group consisting of aryloxy, cycloalkylamino, aralkylamino; and acylamino according to Formula VI;

J is carbon;

R_{11} is absent;

R_{12} is hydrogen, alkyl, alkylamino, aralkylamino, aralkoxy, or aralkylthio;

R_{13} is hydrogen, chlorine, disubstituted amino, alkylthio, or aralkylthio;
R_{15} is hydrogen; and
R_{16} is hydrogen, halo, or alkyl.

41. The method according to Claim 3, wherein said pharmaceutical formulation is a pharmaceutical formulation according to Claim 37.

42. The method according to Claim 3, wherein said pharmaceutical formulation is a pharmaceutical formulation according to Claim 38.

43. The method according to Claim 3, wherein said pharmaceutical formulation is a pharmaceutical formulation according to Claim 39.

44. The method according to Claim 3, wherein said pharmaceutical formulation is a pharmaceutical formulation according to Claim 40. --

THE REMARKS

The correction on Column 8 is to correct a typographical error, which was amended in the Amendment dated December 30, 2003. The error in the patent incurs through the fault of the U.S. Patent and Trademark Office.

All other corrections in the specification are to correct typographical errors incurred through the fault of the U.S. Patent and Trademark Office. The original specification was correct.

The corrections in the claims are to include the three Amendments submitted on November 5, 2004, December 13, 2004, and May 24, 2005. On November 5, 2004, Applicants submitted Amendment after Allowance. On December 13, 2004, Applicants submitted Second Amendment after Allowance. In the Response to Rule 312 Communication dated March 1, 2005, the Examiner states that the amendment filed under 37 CFR 1.312 has been considered and has been entered. On May 24, 2005, Application submitted a Request for Continued Examination, Request for Withdrawal from Patent Issuance, Preliminary Amendment, and Information Disclosure Statements. On the Image File Wrapper of Patent Application Information Retrieval (PAIR), it is indicated that "05-24-2005, Amendment Submitted/Entered with Filing CPA/RCE." However, the above three amendments were completely omitted in the issued patent, through the fault of the U.S. Patent and Trademark Office.

Claim 35 in the patent was canceled in the Amendment dated May 24, 2006. Therefore, all claims subsequent to Claim 35 are renumbered in the Request for Certificate of Correction.

Respectfully submitted,

Date: August 24, 2006

Viola T. Kung, Ph.D. (Reg. No. 41,131)

HOWREY, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 22042
Tel: (650) 798-3570
Fax: (650) 798-3600

PTO/SB/ 44
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO	:	7,018,985
APPLICATION NO.	:	09/643,138
ISSUE DATE	:	March 28, 2006
INVENTOR(S)	:	Boyer, José L., et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

Column 8, at line 66, change "n and p=0.1, or 2" to --n and p=0, 1, or 2--.

Column 9, at line 28, change "Z'=OH" to --Z'=H, OH,--.

Column 18, line 14, change "121.47 NHz" to --121.47 MHz--.

Column 19, line 53, change "(b **24**mg" to --(24mg--.

Column 20, line 43, change "β -10.13" to --δ -10.13--.

Column 20, line 53, change "β 4.10" to --δ 4.10--.

In the Claims:

Column 25, line 13, Claim 1, after "thereof", insert -- and a pharmaceutically acceptable carrier --.

Column 26, line 27, Claim 1, insert --wherein:-- before "X_1, X_2, and X_3 =O".

Column 27, line 32, Claim 1, change "0 to 5" to --1 to 5--.

Column 27, line 58, Claim 1, change "0 to 5" to --1 to 5--.

MAILING ADDRESS OF SENDER:

HOWREY, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 22042

PTO/SB/ 44
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO	:	7,018,985
APPLICATION NO.	:	09/643,138
ISSUE DATE	:	March 28, 2006
INVENTOR(S)	:	Boyer, José L., et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 28, lines 36-37, Claim 1, change "OR1, OR2, OR3, or OR4" to -- OR_1, OR_2, OR_3, or OR_4--.

Column 29, lines 4-5, Claim 1, change "1 to 3" to --0 to 3--.

Column 29, lines 21-22, Claim 1, change "1 to 3" to --0 to 3--.

Column 30, line 51, Claim 1, before "alkyl", delete --an--.

Column 31, line 67 through Column 32, line 2, Claim 1, delete "provided that they incorporate an amino residue from the C-6 position of the purine or the C-4 position of the pyrimidine;".

Column 32, line 8, Claim 1, delete ", as described above"

Column 32, line 14, Claim 1, change "aralkyloxy" to --aralkoxy--.

Column 32, lines 24-25, Claim 1, delete ", such as acetyl, benzoyl, phenylacyl, with or without substituents".

Column 32, line 27, Claim 1, delete "methyl, alkyl,".

Column 32, line 52, Claim 2, change "claim 1" to --claim 36--.

Column 33, line 24, Claim 10, change "a group" to --the group--.

MAILING ADDRESS OF SENDER:

HOWREY, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 22042

PTO/SB/44
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO	:	7,018,985
APPLICATION NO.	:	09/643,138
ISSUE DATE	:	March 28, 2006
INVENTOR(S)	:	Boyer, José L., et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 34, lines 11-12, Claim 19, delete "including skin flaps".

Column 34, line 12, Claim 19, delete "such as breast reduction".

Column 35, lines 8-10, Claim 35, delete "35. The pharmaceutical formulation according to claim **1**, wherein said formulation further comprises a pharmaceutical carrier."

Column 35, line 11, renumber "36" to --35--.

Column 35, line 14, renumber "37" to --36--.

Column 37, line 43, change "0 to 5" to --1 to 5--.

Column 38, line 1, change "0 to 5" to --1 to 5--.

Column 39, lines 11-12, change "1 to 3" to --0 to 3--.

Column 39, lines 26-27, change "1 to 3" to --0 to 3--.

Column 40, line 58, change "aryl, substituted" to --and substituted--.

Column 40, line 59, delete "ad substituted aryl,--.

Column 42, line 4, delete "alkylthio, alkyloxy,".

MAILING ADDRESS OF SENDER:

HOWREY, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 22042

PTO/SB/44
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO	:	7,018,985
APPLICATION NO.	:	09/643,138
ISSUE DATE	:	March 28, 2006
INVENTOR(S)	:	Boyer, José L., et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 42, lines 5-6, delete "aralkylamino, arylamino, diaralkylamino, and diarylamino,".

Column 42, line 6, before "where", insert --and dialkylamino--.

Column 42, lines 8-11, delete ", provided that they incorporate an amino residue from the C-6 position of the purine or the C-4 position of the pyrimidine".

Column 42, line 25, change "aralkyloxy" to --aralkoxy--.

Column 42, lines 35-36, delete ", such as acetyl, benzoyl, phenylacyl, with or without substituents".

Column 42, line 39, delete "methyl, alkyl,".

Column 42, line 66, renumber "38" to --37--.

MAILING ADDRESS OF SENDER:

HOWREY, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 22042

PTO/SB/ 44
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 7,018,985
APPLICATION NO. : 09/643,138
ISSUE DATE : March 28, 2006
INVENTOR(S) : Boyer, José L., et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 44, line 32, insert the following claims:

--38. The pharmaceutical formulation according to Claim 1, wherein said compound is Formula Ia, wherein

X_1, X_2, and X_3=O;

T, V, and W= O;

M= H, NH_4^+, Na^+ or other pharmaceutically-acceptable inorganic or organic counterion;

Y'= H, OH, or OR_1, where OR_1 falls under the definition of general formula III;

Z'= OH or OR_2, where OR_2 falls under the definition of general formula III;

Z= OH or OR_3, where OR_3 falls under the definition of general formula III;

Y= H, OH, or OR_4, where OR_4 falls under the definition of general formula III;

provided that at least one of Y', Z', Z, and Y is OR_1, OR_2, OR_3, or OR_4, respectively;

D_1 =O;

D_2 =O;

B and B' are purine or pyrimidine residues according to general formulas IV and V;

m and p= 0, 1 or 2;

n= 0 or 1.

such that the sum of m+n+p is from 0 to 5.

MAILING ADDRESS OF SENDER:

HOWREY, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 22042

PTO/SB/ 44
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO	:	7,018,985
APPLICATION NO.	:	09/643,138
ISSUE DATE	:	March 28, 2006
INVENTOR(S)	:	Boyer, José L., et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

39. The pharmaceutical formulation according to Claim 1, wherein said compound is Formula Ib, wherein

A is M or alkyl;

X_1 and X_2= O;

T, V, and W= O;

M is selected from the group consisting of H, NH_4^+, Na^+ and other pharmaceutically-acceptable inorganic or organic counterion;

Y'= OR_1, where OR_1 falls under the definition of general formula III;

Z'= OR_2, where OR_2 falls under the definition of general formula III;

D_1 =O or C;

B' is purine or pyrimidine residue according to general formulas IV and V;

n and p are 0, 1, or 2 such that the sum of n+p is from 0 to 3.

MAILING ADDRESS OF SENDER:

HOWREY, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 22042

PTO/SB/44
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO	:	7,018,985
APPLICATION NO.	:	09/643,138
ISSUE DATE	:	March 28, 2006
INVENTOR(S)	:	Boyer, José L., et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

40. The pharmaceutical formulation according to Claim 1, wherein

R_{10} and R_{14} are selected from the group consisting of aryloxy, cycloalkylamino, aralkylamino; and acylamino according to Formula VI;

J is carbon;

R_{11} is absent;

R_{12} is hydrogen, alkyl, alkylamino, aralkylamino, aralkoxy, or aralkylthio;

R_{13} is hydrogen, chlorine, disubstituted amino, alkylthio, or aralkylthio;

R_{15} is hydrogen; and

R_{16} is hydrogen, halo, or alkyl.

41. The method according to Claim 3, wherein said pharmaceutical formulation is a pharmaceutical formulation according to Claim 37.

42. The method according to Claim 3, wherein said pharmaceutical formulation is a pharmaceutical formulation according to Claim 38.

MAILING ADDRESS OF SENDER:

HOWREY, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 22042

PTO/SB/44
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO	:	7,018,985
APPLICATION NO.	:	09/643,138
ISSUE DATE	:	March 28, 2006
INVENTOR(S)	:	Boyer, José L., et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

43. The method according to Claim 3, wherein said pharmaceutical formulation is a pharmaceutical formulation according to Claim 39.

44. The method according to Claim 3, wherein said pharmaceutical formulation is a pharmaceutical formulation according to Claim 40. --

MAILING ADDRESS OF SENDER:

HOWREY, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 22042